Recursion Pharmaceuticals - Class A (RXRX) closed at $3.19 on November 13, 2026, down 4.4% from the previous close, on volume of 15,802,207 shares (30-day average 26,193,723).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Calendar Put Spread | 23-Oct : 30-Oct-26 3.5 P | 2,650 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Recursion Pharmaceuticals Earnings Call Signals Clinical Momentum
TipRanks (Sat, 14-Nov 10:22 PM ET)
Recursion to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 11-Nov 8:00 AM ET)
Portal Innovations and Altitude Lab Partner to Strengthen Utah's Life Sciences Startup Ecosystem
Business Wire (Thu, 5-Nov 11:15 AM ET)
Globe Newswire (Mon, 2-Nov 4:30 PM ET)
Globe Newswire (Mon, 2-Nov 4:25 PM ET)
Recursion Appoints Fred Hassan as Chair of the Board
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Globe Newswire (Mon, 26-Oct 4:05 PM ET)
Globe Newswire (Thu, 15-Oct 8:45 AM ET)
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Globe Newswire (Thu, 15-Oct 8:30 AM ET)
Globe Newswire (Thu, 15-Oct 8:22 AM ET)
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Recursion Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol RXRX.
As of November 13, 2026, RXRX stock price declined to $3.18 with 15,802,207 million shares trading.
RXRX has a beta of 2.49, meaning it tends to be more sensitive to market movements. RXRX has a correlation of 0.20 to the broad based SPY ETF.
RXRX has a market cap of $1.90 billion. This is considered a Small Cap stock.
Last quarter Recursion Pharmaceuticals - Class A reported $19 million in Revenue and -$.22 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.01.
In the last 3 years, RXRX traded as high as $15.74 and as low as $2.77.
The top ETF exchange traded funds that RXRX belongs to (by Net Assets): ARKK, ARKE, VTI, XBI, ARKG.
RXRX has underperformed the market in the last year with a price return of -26.4% while the SPY ETF gained +13.4%. RXRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.8% and -21.0%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
RXRX support price is $3.14 and resistance is $3.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RXRX shares will trade within this expected range on the day.
